Cargando…

P1336: ANTIVIRAL EXPOSURE TO GANCICLOVIR AND VALGANCICLOVIR IS NOT ASSOCIATED WITH INCREASED INCIDENCE OF RELAPSE OR SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

Detalles Bibliográficos
Autores principales:	Duarte, D., Duarte, S., Sol dos Reis, C., Silva Coelho, P., Leite, L., Branca, R., Roncon, S., Pinho Vaz, C., Campos, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430321/ http://dx.doi.org/10.1097/01.HS9.0000848208.53297.5e

Ejemplares similares

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
por: Galar, Alicia, et al.
Publicado: (2021)

P1372: REAL-WORLD RETROSPECTIVE ANALYSIS OF INFECTIOUS COMPLICATIONS AFTER RUXOLITNIB USE IN ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE
por: Sol Reis, C., et al.
Publicado: (2022)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
por: Mozaffar, Maryam, et al.
Publicado: (2018)

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir
por: Yang, Wenyu, et al.
Publicado: (2023)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

P1365: DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM A RETROSPECTIVE STUDY
por: Rochate, D., et al.
Publicado: (2022)

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
por: Perrottet, Nancy, et al.
Publicado: (2010)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

Allogeneic stem cell transplant in relapsed/ refractory Hodgkin lymphoma: A 21 years’ experience
por: Couto, Maria Eduarda, et al.
Publicado: (2022)

P1383: EXTRAMEDULLARY RELAPSE OF ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE-CENTER EXPERIENCE
por: Vasconcelos, F., et al.
Publicado: (2022)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
por: Tripathy, Koushik, et al.
Publicado: (2017)

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure
por: Jorga, Karin, et al.
Publicado: (2018)

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
por: Cheng, Yu-Chun, et al.
Publicado: (2021)

Ganciclovir therapeutic drug monitoring in transplant recipients
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014)

1336. Outcomes of COVID-19 in Recent Kidney Transplants Recipients at a Large Transplant Center in Miami
por: Mendoza, Maria A, et al.
Publicado: (2021)

Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach
por: Lalagkas, Panagiotis Nikolaos, et al.
Publicado: (2023)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

The antiviral drug ganciclovir does not inhibit microglial proliferation and activation
por: Skripuletz, Thomas, et al.
Publicado: (2015)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data
por: Murray, Jillian, et al.
Publicado: (2020)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients
por: Dvořáčková, Eliška, et al.
Publicado: (2022)

Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation
por: Ding, Zhaoqing, et al.
Publicado: (2014)

An Alternative Approach to Isoganciclovir: A Prominent Impurity in the Antiviral Drug Ganciclovir
por: Sundaram, Dhanraj T. S. S., et al.
Publicado: (2015)

Ganciclovir-resistant cytomegalovirus infection in renal transplantation
por: Vaz, Raquel, et al.
Publicado: (2014)

Association of Epstein-Barr virus infection with allogeneic hematopoietic stem cell transplantation in patients in Portugal
por: Marinho-Dias, Joana, et al.
Publicado: (2019)

1571. Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis Among CMV Serology Mismatched (Donor+/Recipient−) Lung Transplant Recipients
por: Tomko, Heather, et al.
Publicado: (2018)

Sex Differences in the Treatment of Uveal Melanoma in a Group of 1336 Patients
por: Romanowska-Dixon, Bożena, et al.
Publicado: (2023)

P1336: LONGTERM EX VIVO EXPANSION OF FUNCTIONAL MURINE AND HUMAN HEMATOPOIETIC STEM CELLS USING BONE-LINING STROMAL CELLS
por: Klein, Lukas, et al.
Publicado: (2023)

Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study
por: Egan, J. J., et al.
Publicado: (2011)

A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol
por: Takhar, Jaskirat S, et al.
Publicado: (2019)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

Efficacy of low-dose valganciclovir in CMV R+ lung transplant recipients: a retrospective comparative analysis
por: Hunt, Jessica, et al.
Publicado: (2021)

Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant Cytomegalovirus Infection in Lung Transplant Recipients
por: Patel, Twisha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p25r2uodceah0fv0j0fghpimqk